evidence: Clinicians across the country have experienced a rise in patient requests to avoid blood products from donors vaccinated against SARS-CoV-2 (referred hereafter using the more commonly used disease term COVID-19). Patient concerns regarding blood transfusions from donors vaccinated against COVID-19 are often centered around vaccine-related worries that can be propagated across social media platforms. This issue has become so pervasive that the Association for the Advancement of Blood & Biotherapies (Bethesda, Maryland), America’s Blood Centers (Washington, D.C.), and the American Red Cross (Washington, D.C.) issued a joint statement earlier this year reassuring patients of the safety of the blood supply in America.1 [...] Patient concerns over the safety of the blood supply because of potential COVID-19 vaccination status of donors is an increasingly encountered clinical dilemma. Requests to avoid blood products from donors vaccinated against COVID-19 present a number of challenges given that it is not possible in our current blood banking infrastructure to distinguish units of blood that have been received from donors vaccinated or not vaccinated against COVID-19. Collaborative, nonhurried, and nonjudgmental conversations using a shared decision-making framework are paramount when working through this concern with patients in the perioperative period. Policy development should be implemented at the institutional level to provide consistent guidance to clinicians, including what options are available for a particular patient.